EDWARD E MITRE, MD
Osteopathic Medicine at Medical Center Dr, Rockville, MD

License number
Maryland D0058473
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Maryland D0058473
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
9901 Medical Center Dr, Rockville, MD 20850
Phone
(301) 279-6021
(240) 453-5702 (Fax)
(301) 652-5771
(301) 652-6332 (Fax)

Professional information

Edward E Mitre Photo 1

Dr. Edward E Mitre, Bethesda MD - MD (Doctor of Medicine)

Specialties:
Infectious Disease Medicine
Address:
4301 Jones Bridge Rd STE B4104, Bethesda 20814
9901 Medical Center Dr, Rockville 20850
(301) 279-6021 (Phone), (240) 453-5702 (Fax)
UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES-UROLOGY
4301 Jones Bridge Rd, Bethesda 20814
(301) 295-9822 (Phone), (301) 319-6965 (Fax)
Certifications:
Infectious Disease, 2011, Internal Medicine, 1998
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
4301 Jones Bridge Rd STE B4104, Bethesda 20814
9901 Medical Center Dr, Rockville 20850
UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES-UROLOGY
4301 Jones Bridge Rd, Bethesda 20814
Shady Grove Adventist Hospital
9901 Medical Center Dr, Rockville 20850
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 1995


Edward Mitre Photo 2

Methods Of Treating Autoimmune Diseases With Anti-Fceri Antibodies

US Patent:
2013017, Jul 4, 2013
Filed:
Sep 14, 2011
Appl. No.:
13/821961
Inventors:
Edward E. Mitre - Rockville MD, US
Marc P. Hübner - Nordrheinwestfalen, DE
Assignee:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC - Bethesda MD
International Classification:
A61K 39/395
US Classification:
4241331, 4241731, 4241531, 4241421
Abstract:
Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases.